The Vigabatrin REMS Program is required by the FDA to make sure notified risk-benefit choices before initiating therapy, and to ensure appropriate use of vigabatrin while individuals are treated. It is not possible for your healthcare provider to understand when vision loss will occur.
It is recommended that your healthcare provider examination your (or your youngster's) vision before or within 4 weeks after starting SABRIL and at least every 3 months throughout treatment up until SABRIL is quit. If you or your child have any side impact that bothers you or that does not go away, tell your health care service provider.
If you are expectant or mean to obtain pregnant, inform your medical care provider. If vision testing can not be done, your doctor might continue prescribing SABRIL, but will not have the ability to expect any type of vision loss. Your healthcare service provider might quit prescribing SABRIL for you (or your child)if vision examinations are not done regularly.